City

Clinical trials near Las Vegas, United States

Active studies with a listed research site in Las Vegas, United States.

21active studies

12recruiting now

7countries represented

74largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Obesity, OverweightCondition

LY3305677, LY3841136Treatment

Argentina, United States56 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06143956See eligibility →

Recruiting nowPhase 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Obesity, OverweightCondition

Macupatide, EloralintideTreatment

Argentina, Australia42 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07215559See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Obesity, OverweightCondition

Maridebart Cafraglutide, PlaceboTreatment

Japan, Puerto Rico37 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684144See eligibility →

Recruiting nowPhase 3

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Obesity, OverweightCondition

aleniglipron, aleniglipronTreatment

United States74 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-09-01 · NCT07654374See eligibility →

Recruiting nowPhase 3

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Obesity or OverweightCondition

Maridebart CafraglutideTreatment

Puerto Rico, United States45 locations

AmgenSponsor

Updated 2026-08-27 · NCT07575399See eligibility →

Recruiting nowNot applicable

Assess the Effects of Replacing Foods High in Refined Carbohydrates With Avocado on Biomarkers of Inflammation.

Overweight (BMI > 25), Obesity (BMI>30)Condition

Avocado, ControlTreatment

United States2 locations

Midwest Center for Metabolic and Cardiovascular ResearchSponsor

Updated 2026-08-27 · NCT07566325See eligibility →

Recruiting nowPhase 2

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)

Overweight, ObesityCondition

PF-08653945, PF-08653944Treatment

Canada, United States65 locations

PfizerSponsor

Updated 2026-08-17 · NCT07575932See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Obesity, OverweightCondition

Aleniglipron, PlaceboTreatment

United States71 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-08-10 · NCT07654361See eligibility →

Recruiting nowPhase 2

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Overweight, ObesityCondition

Macupatide, EloralintideTreatment

United States40 locations

Eli Lilly and CompanySponsor

Updated 2026-08-06 · NCT07589608See eligibility →

Recruiting nowPhase 2

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

Overweight or Obesity and Elevated Liver FatCondition

Maridebart cafraglutide, PlaceboTreatment

United States23 locations

AmgenSponsor

Updated 2026-06-18 · NCT07441252See eligibility →

Recruiting nowPhase 1

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

Obesity & OverweightCondition

CX11, PlaceboTreatment

United States2 locations

Corxel PharmaceuticalsSponsor

Updated 2026-06-17 · NCT07652047See eligibility →

Recruiting nowPhase 2

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

Type 2 DiabetesCondition

icovamenib 100 mg, PlaceboTreatment

United States17 locations

Biomea Fusion Inc.Sponsor

Updated 2026-06-15 · NCT07502508See eligibility →

Opening soonPhase 2

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Atherosclerosis, Cardiovascular DiseaseCondition

Clazakizumab, PlaceboTreatment

Argentina, Japan47 locations

Eli Lilly and CompanySponsor

Updated 2026-08-25 · NCT07783802See eligibility →

Opening soonPhase 3

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Overweight, ObesityCondition

zenagamtide, PlaceboTreatment

United States37 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07720271See eligibility →

Active, not recruitingPhase 2

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

Overweight, Type 2 DiabetesCondition

Petrelintide, PlaceboTreatment

United States48 locations

Zealand PharmaSponsor

Updated 2026-08-21 · NCT06926842See eligibility →

Active, not recruitingPhase 2

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

LY3841136, TirzepatideTreatment

Argentina, United States52 locations

Eli Lilly and CompanySponsor

Updated 2026-07-17 · NCT06603571See eligibility →

Active, not recruitingPhase 1

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

Obese But Otherwise Healthy ParticipantsCondition

CRB-913, PlaceboTreatment

United States15 locations

Corbus Pharmaceuticals Inc.Sponsor

Updated 2026-05-29 · NCT07310901See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

ObesityCondition

Retatrutide, PlaceboTreatment

Canada, United Kingdom53 locations

Eli Lilly and CompanySponsor

Updated 2026-03-03 · NCT06859268See eligibility →

Active, not recruitingPhase 2

Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

Endocrinology, Diabetes, Type IICondition

AZD6234, Placebo to matchTreatment

United States18 locations

AstraZenecaSponsor

Updated 2026-03-03 · NCT06851858See eligibility →

Active, not recruitingNot applicable

Study to Evaluate the Efficacy of an Avocado Dietary Supplement

Overweight, Metabolic HealthCondition

Metavo Supplement, PlaceboTreatment

United States1 locations

SP Nutraceuticals Inc.Sponsor

Updated 2026-01-21 · NCT07354308See eligibility →

Active, not recruitingPhase 2

Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

ObesityCondition

Nimacimab injection, Nimacimab placebo injectionTreatment

United States16 locations

Skye Bioscience, Inc.Sponsor

Updated 2026-01-14 · NCT06577090See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Las Vegas, United States

Current studies

Related cities